Skip to main content
Premium Trial:

Request an Annual Quote

Barbara Ann Karmanos Cancer Institute Receives $325K Lymphoma Research Grant

NEW YORK – The Barbara Ann Karmanos Cancer Institute said on Monday that it has received a $325,372 grant from the U Can-Cer Vive Foundation to support research on diffuse large B-cell lymphoma (DLBCL).

The grant will fund a pilot study that will measure circulating tumor DNA (ctDNA) to help identify patients likely to relapse after autologous stem cell transplantation.

DLBCL is an aggressive type of non-Hodgkin lymphoma that affects B lymphocytes in a patient's tissue. The disease is typically detected using a tissue biopsy based on expression of B-cell marker proteins.

Patients are usually treated with a combination of chemotherapy and monoclonal antibody drugs that target the disease's cancerous B cells. However, about 30 percent of patients relapse after standard treatment.

Dipenkumar Modi, study leader and a member of Detroit-based Karmanos' hematology multidisciplinary team, said in a statement that current methods for detecting DLBCL are not sensitive enough to spot patients who may relapse after transplant.

"Through this study, we hope to find a biomarker to help identify patients at high risk of relapse and predict transplant outcomes," Modi added. "This will have a significant impact on patient care, and the results of this study will set the foundation for precision medicine-driven treatment strategies in DLBCL."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.